| nr |
titel |
auteur |
tijdschrift |
jaar |
jaarg. |
afl. |
pagina('s) |
type |
| 1 |
Doubts hang over PEPFAR finances
|
The Lancet HIV,
|
|
2017
|
4 |
5 |
p. e189-
1 p.
|
artikel
|
| 2 |
From HIV infection to therapeutic response: a population-based longitudinal HIV cascade-of-care study in KwaZulu-Natal, South Africa
|
Haber, Noah
|
|
2017
|
4 |
5 |
p. e223-e230
nvt p.
|
artikel
|
| 3 |
HIV prevention resources: time to move toward affordability
|
Kimmel, April D
|
|
2017
|
4 |
5 |
p. e191-e193
nvt p.
|
artikel
|
| 4 |
Is 90-90-90 achievable?
|
Rutherford, George W
|
|
2017
|
4 |
5 |
p. e193-e194
nvt p.
|
artikel
|
| 5 |
PrEP for key populations in combination HIV prevention in Nairobi: a mathematical modelling study
|
Cremin, Ide
|
|
2017
|
4 |
5 |
p. e214-e222
nvt p.
|
artikel
|
| 6 |
Switching from efavirenz, emtricitabine, and tenofovir disoproxil fumarate to tenofovir alafenamide coformulated with rilpivirine and emtricitabine in virally suppressed adults with HIV-1 infection: a randomised, double-blind, multicentre, phase 3b, non-inferiority study
|
DeJesus, Edwin
|
|
2017
|
4 |
5 |
p. e205-e213
nvt p.
|
artikel
|
| 7 |
Switching from tenofovir disoproxil fumarate to tenofovir alafenamide coformulated with rilpivirine and emtricitabine in virally suppressed adults with HIV-1 infection: a randomised, double-blind, multicentre, phase 3b, non-inferiority study
|
Orkin, Chloe
|
|
2017
|
4 |
5 |
p. e195-e204
nvt p.
|
artikel
|
| 8 |
Tenofovir prodrugs: similar but not the same
|
Bruggemans, Anne
|
|
2017
|
4 |
5 |
p. e190-e191
nvt p.
|
artikel
|
| 9 |
The role of testing in HIV prevention
|
The Lancet HIV,
|
|
2017
|
4 |
5 |
p. e189-
1 p.
|
artikel
|
Tijdschrift beschrijving